Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Technique May Provide Low-Cost Pathogen Testing

By LabMedica International staff writers
Posted on 12 Jul 2016
Researchers are developing a rapid pyrogen-detection stick-test for detecting presence of pathogens and allergens. More...
The test has potential applications in clinical diagnostics as well as in food, pharmaceutical, and hospital environment testing.

Currently pyrogens (fragments of pathogens) can only be detected with laboratory equipment that makes testing costly and laborious. A widely used standard test is the detection of LPS, a structure that is present in the membrane of certain bacteria. At present this test takes around 2 hours. Some pyrogens can even only be detected in animal experiment.

Researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB (Stuttgart, Germany) are developing a rapid and cost-effective test, ImmuStick, which can be carried out directly in situ without laboratory equipment and specialist knowledge.

“The ImmuStick can even detect pathogens outside the body – on medical devices or in hospital rooms for example. However, the technology would certainly also be of interest for testing human blood for germs or allergies,” said Dr. Anke Burger-Kentischer. Working as simply as a pregnancy test, ImmuStick is a test strip onto which a few drops of sample fluid are applied. If the fluid contains pyrogens, this is indicated by a color in a viewing window.

Feasibility was demonstrated using an ImmuStick with immune receptors specific for testing samples for the bacterial pyrogen LPS. “We were able to show that it works very well,” said project manager Dr. Burger-Kentischer, “Together with industrial partners, we now want to develop it into a product, [and] we are currently testing further immune receptors that are specific for other pyrogens.“

ImmuStick is of interest for blood analysis as pyrogens in the blood often lead to sepsis. “However, blood is a special challenge as it is complex and contains many constituent parts. But in the medium term we are aiming at blood analysis,” said Dr. Burger-Kentischer.

Also envisaged are applications outside the clinical lab sector. Pyrogens include certain allergy trigger factors and can be a problem where hygiene is of particular importance, so ImmuStick could be used in the food and pharmaceutical industries as well as in hospitals on, for example, intensive care wards. Costly and laborious laboratory tests would therefore no longer be needed or could be supplemented. The IGB researchers are seeking cooperation partners to help further develop ImmuStick.

Related Links:
Fraunhofer Institute



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.